Back to Search Start Over

Human thymopoiesis produces polyspecific CD8 + α/β T cells responding to multiple viral antigens.

Authors :
Quiniou V
Barennes P
Mhanna V
Stys P
Vantomme H
Zhou Z
Martina F
Coatnoan N
Barbie M
Pham HP
Clémenceau B
Vie H
Shugay M
Six A
Brandao B
Mallone R
Mariotti-Ferrandiz E
Klatzmann D
Source :
ELife [Elife] 2023 Mar 30; Vol. 12. Date of Electronic Publication: 2023 Mar 30.
Publication Year :
2023

Abstract

T-cell receptors (TCRs) are formed by stochastic gene rearrangements, theoretically generating >10 <superscript>19</superscript> sequences. They are selected during thymopoiesis, which releases a repertoire of about 10 <superscript>8</superscript> unique TCRs per individual. How evolution shaped a process that produces TCRs that can effectively handle a countless and evolving set of infectious agents is a central question of immunology. The paradigm is that a diverse enough repertoire of TCRs should always provide a proper, though rare, specificity for any given need. Expansion of such rare T cells would provide enough fighters for an effective immune response and enough antigen-experienced cells for memory. We show here that human thymopoiesis releases a large population of clustered CD8 <superscript>+</superscript> T cells harboring α/β paired TCRs that (i) have high generation probabilities and (ii) a preferential usage of some V and J genes, (iii) which CDR3 are shared between individuals, and (iv) can each bind and be activated by multiple unrelated viral peptides, notably from EBV, CMV, and influenza. These polyspecific T cells may represent a first line of defense that is mobilized in response to infections before a more specific response subsequently ensures viral elimination. Our results support an evolutionary selection of polyspecific α/β TCRs for broad antiviral responses and heterologous immunity.<br />Competing Interests: VQ Valentin Quiniou is affiliated with Parean biotechnologies. The author has no financial interests to declare, PB, VM, PS, HV, ZZ, FM, NC, MB, BC, HV, MS, AS, BB, RM, EM, DK No competing interests declared, HP Hang-Phuong Pham is affiliated with ILTOO pharma and Parean biotechnologies. The author hasno financial interests to declare<br /> (© 2023, Quiniou et al.)

Details

Language :
English
ISSN :
2050-084X
Volume :
12
Database :
MEDLINE
Journal :
ELife
Publication Type :
Academic Journal
Accession number :
36995951
Full Text :
https://doi.org/10.7554/eLife.81274